5-FLUOROURACIL BY PROTRACTED VENOUS INFUSION - A REVIEW OF RECENT CLINICAL-STUDIES

被引:55
作者
HANSEN, RM
机构
[1] Division of Hematology/Oncology Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
关键词
D O I
10.3109/07357909109039875
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacokinetics of continuous infusion 5-fluorouracil make it an ideal drug to administer as a protracted infusion (continuous infusion more than 30 days). During the last decade numerous clinical studies have been conducted to evaluate the efficacy of 5-fluorouracil (5FU) administered as a protracted venous infusion. Phase II studies in metastatic colorectal cancer in 345 patients have demonstrated an average response rate of 36% (range 15-59%) and a prospective randomized study performed by the Mid-Atlantic Oncology Program (MAOP) has confirmed a higher response rate with 5FU infusion compared with a bolus schedule. Phase II studies in refractory carcinoma of the breast in 177 patients have demonstrated a 30% response rate (range 17-50%); studies in pancreatic, gastric, and refractory prostate cancer have also demonstrated clinical utility. The major toxicities of 5FU infusion are mucositis and hand-foot syndrome; life-threatening myelosuppression is rare and treatment-related deaths have not been reported. 5FU infusion is a useful palliative treatment for many adult patients with advanced malignancies.
引用
收藏
页码:637 / 642
页数:6
相关论文
共 42 条
[1]  
BELT RJ, 1985, P ASCO, V4, P90
[2]  
BENEDETTO P, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P92
[3]  
CABALLERO GA, 1985, CANCER TREAT REP, V69, P13
[4]   CONTINUOUS INFUSION OR BOLUS INJECTION IN CANCER-CHEMOTHERAPY [J].
CARLSON, RW ;
SIKIC, BI .
ANNALS OF INTERNAL MEDICINE, 1983, 99 (06) :823-833
[5]  
COSTANZO FD, 1989, P AM SOC CLIN ONCOL, V8, P106
[6]   PROSPECTIVE RANDOMIZED COMPARISON OF FLUOROURACIL VERSUS FLUOROURACIL AND HIGH-DOSE CONTINUOUS INFUSION LEUCOVORIN CALCIUM FOR THE TREATMENT OF ADVANCED MEASURABLE COLORECTAL-CANCER IN PATIENTS PREVIOUSLY UNEXPOSED TO CHEMOTHERAPY [J].
DOROSHOW, JH ;
MULTHAUF, P ;
LEONG, L ;
MARGOLIN, K ;
LITCHFIELD, T ;
AKMAN, S ;
CARR, B ;
BERTRAND, M ;
GOLDBERG, D ;
BLAYNEY, D ;
ODUJINRIN, O ;
DELAP, R ;
SHUSTER, J ;
NEWMAN, E .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :491-501
[7]   A RANDOMIZED TRIAL OF FLUOROURACIL AND FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA [J].
ERLICHMAN, C ;
FINE, S ;
WONG, A ;
ELHAKIM, T .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :469-475
[8]  
FAINTUCH J S, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P93
[9]   CONTINUOUS 5-FLUOROURACIL (5FU) INFUSION IN CARCINOMA OF THE PANCREAS - A PHASE-II STUDY [J].
HANSEN, R ;
QUEBBEMAN, E ;
RITCH, P ;
CHITAMBAR, C ;
ANDERSON, T .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 295 (02) :91-93
[10]   CONTINUOUS 5-FLUOROURACIL INFUSION IN REFRACTORY CARCINOMA OF THE BREAST [J].
HANSEN, R ;
QUEBBEMAN, E ;
BEATTY, P ;
RITCH, P ;
ANDERSON, T ;
JENKINS, D ;
FRICK, J ;
AUSMAN, R .
BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (02) :145-149